Skip to main content
Figure 1 | BMC Cancer

Figure 1

From: Platelet factor-4 and its p17-70 peptide inhibit myeloma proliferation and angiogenesis in vivo

Figure 1

PF4 and p17-70 attenuate VEGF production in myeloma cells in vitro. (A) Identification of the expression and integration of foreign genes (A: 1-2): RT-PCR analysis of RNA in U266 cells transfected with different retroviruses. M: DNA size marker; lane 1: p17-70-infected U266 cells (150 bp); lane 2: PF4-infected U266 cells (170 bp). (B) Western blotting assay of selected MM cells. Control groups: U266-neo, RPMI8226-neo, and LP-1-neo; p17-70 groups: U266-p17-70, RPMI8226-p17-70, and LP-1-p17-70. (C) VEGF levels in the supernatants of three sorts of MM cells. There were significant differences in the VEGF levels in the supernatants of the U266 cells among the groups (PF4: 160.36 ± 8.80 pg/ml, p17-70: 98.25 ± 9.65 pg/ml, U266-neo: 663.58 ± 142.16 pg/ml, both of P < 0.01). There were significant differences in the VEGF levels in the supernatants of the RPMI8226 cells among the groups (PF4: 147.61 ± 5.15 pg/ml, p17-70: 86.73 ± 4.81 pg/ml, RPMI8226-neo: 848.61 ± 216.15 pg/ml both of P < 0.01). There were significant differences in the VEGF levels in the supernatants of the LP-1 cells among the groups (PF4: 167.92 ± 10.28 pg/ml, p17-70: 109.32 ± 5.28 pg/ml pg/ml, LP-1-neo: 701.73 ± 192.81 pg/ml both of P < 0.01). Figures represents the three independent experiments done in triplicate (**, P < 0.01).

Back to article page